Current Therapeutic Strategies in Patients with Oropharyngeal Squamous Cell Carcinoma: Impact of the Tumor HPV Status
Abstract
:Simple Summary
Abstract
1. Introduction
2. HPV-Positive and HPV-Negative OPSCC Are Two Distinct Diseases
3. Standard Therapeutic Options in OPSCC Patients
3.1. Surgical Treatment
3.1.1. Evolution of Surgical Techniques
3.1.2. Therapeutic Strategies Involving Upfront Surgery
3.2. Non-Surgical Therapeutic Strategies
4. Impact of the HPV Tumor Status on Therapeutic Strategy
4.1. Early-Stage OPSCC
4.2. Locally Advanced Resectable OPSCC
4.3. Locally-Advanced Unresectable OPSCC
4.4. Recurrent and/or Metastatic OPSCC
5. Current Research and Future Directions
6. Conclusions
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
References
- Mahal, B.A.; Catalano, P.J.; Haddad, R.I.; Hanna, G.J.; Kass, J.I.; Schoenfeld, J.D.; Tishler, R.B.; Margalit, D.N. Incidence and Demographic Burden of HPV-Associated Oropharyngeal Head and Neck Cancers in the United States. Cancer Epidemiol. Biomark. Prev. 2019, 28, 1660–1667. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Megwalu, U.C.; Sirjani, D.; Devine, E.E. Oropharyngeal squamous cell carcinoma incidence and mortality trends in the United States, 1973–2013. Laryngoscope 2017, 128, 1582–1588. [Google Scholar] [CrossRef]
- Zevallos, J.P.; Kramer, J.R.; Sandulache, V.C.; Massa, S.T.; Hartman, C.M.; Mazul, A.L.; Wahle, B.M.; Gerndt, S.P.; Sturgis, E.M.; Chiao, E.Y. National trends in oropharyngeal cancer incidence and survival within the Veterans Affairs Health Care System. Head Neck 2020, 43, 108–115. [Google Scholar] [CrossRef] [PubMed]
- Osazuwa-Peters, N.; Simpson, M.C.; Massa, S.T.; Boakye, E.A.; Antisdel, J.L.; Varvares, M.A. 40-year incidence trends for oropharyngeal squamous cell carcinoma in the United States. Oral Oncol. 2017, 74, 90–97. [Google Scholar] [CrossRef]
- Timbang, M.R.; Sim, M.W.; Bewley, A.F.; Farwell, D.G.; Mantravadi, A.; Moore, M.G. HPV-related oropharyngeal cancer: A review on burden of the disease and opportunities for prevention and early detection. Hum. Vaccines Immunother. 2019, 15, 1920–1928. [Google Scholar] [CrossRef] [PubMed]
- Guily, J.L.S.; Rousseau, A.; Baujat, B.; Périé, S.; Schultz, P.; Barry, B.; Dufour, X.; Malard, O.; Pretet, J.-L.; Clavel, C.; et al. Oropharyngeal cancer prognosis by tumour HPV status in France: The multicentric Papillophar study. Oral Oncol. 2017, 67, 29–36. [Google Scholar] [CrossRef]
- Bhatia, A.; Burtness, B. Human Papillomavirus–Associated Oropharyngeal Cancer: Defining Risk Groups and Clinical Trials. J. Clin. Oncol. 2015, 33, 3243–3250. [Google Scholar] [CrossRef]
- Mehanna, H.; Evans, M.; Beasley, M.; Chatterjee, S.; Dilkes, M.; Homer, J.; O’Hara, J.; Robinson, M.; Shaw, R.; Sloan, P. Oropharyngeal cancer: United Kingdom National Multidisciplinary Guidelines. J. Laryngol. Otol. 2016, 130, S90–S96. [Google Scholar] [CrossRef]
- Maschio, F.; Lejuste, P.; Ilankovan, V. Evolution in the management of oropharyngeal squamous cell carcinoma: Systematic review of outcomes over the last 25 years. Br. J. Oral Maxillofac. Surg. 2019, 57, 101–115. [Google Scholar] [CrossRef]
- Bozec, A.; Culié, D.; Poissonnet, G.; Dassonville, O. Current role of primary surgical treatment in patients with head and neck squamous cell carcinoma. Curr. Opin. Oncol. 2019, 31, 138–145. [Google Scholar] [CrossRef] [PubMed]
- Culié, D.; Garrel, R.; Viotti, J.; Schiappa, R.; Chamorey, E.; Fakhry, N.; Lallemant, B.; Vergez, S.; Dupret-Bories, A.; Dassonville, O.; et al. Impact of HPV-associated p16-expression and other clinical factors on therapeutic decision-making in patients with oropharyngeal cancer: A GETTEC multicentric study. Eur. J. Surg. Oncol. (EJSO) 2018, 44, 1908–1913. [Google Scholar] [CrossRef] [PubMed]
- Haigentz, M.; Silver, C.E.; Corry, J.; Genden, E.M.; Takes, R.P.; Rinaldo, A.; Ferlito, A. Current trends in initial management of oropharyngeal cancer: The declining use of open surgery. Eur. Arch. Oto-Rhino-Laryngol. 2009, 266, 1845–1855. [Google Scholar] [CrossRef]
- Price, J.; West, C.; Mistry, H.; Betts, G.; Bishop, P.; Kennedy, J.; Dixon, L.; Homer, J.; Garcez, K.; Lee, L.; et al. Improved survival prediction for oropharyngeal cancer beyond TNMv8. Oral Oncol. 2021, 115, 105140. [Google Scholar] [CrossRef] [PubMed]
- Boscolo-Rizzo, P.; Gava, A.; Baggio, V.; Marchiori, C.; Stellin, M.; Fuson, R.; Lamon, S.; DA Mosto, M.C. Matched Survival Analysis in Patients with Locoregionally Advanced Resectable Oropharyngeal Carcinoma: Platinum-Based Induction and Concurrent Chemoradiotherapy Versus Primary Surgical Resection. Int. J. Radiat. Oncol. 2011, 80, 154–160. [Google Scholar] [CrossRef] [PubMed]
- Culié, D.; Viotti, J.; Modesto, A.; Schiappa, R.; Chamorey, E.; Dassonville, O.; Poissonnet, G.; Guelfucci, B.; Bizeau, A.; Vergez, S.; et al. Upfront surgery or definitive radiotherapy for patients with p16-negative oropharyngeal squamous cell carcinoma. A GETTEC multicentric study. Eur. J. Surg. Oncol. (EJSO) 2020, 47, 367–374. [Google Scholar] [CrossRef] [PubMed]
- Bozec, A.; Demez, P.; Gal, J.; Chamorey, E.; Louis, M.-Y.; Blanchard, D.; De Raucourt, D.; Merol, J.-C.; Brenet, E.; Dassonville, O.; et al. Long-term quality of life and psycho-social outcomes after oropharyngeal cancer surgery and radial forearm free-flap reconstruction: A GETTEC prospective multicentric study. Surg. Oncol. 2018, 27, 23–30. [Google Scholar] [CrossRef] [PubMed]
- Kumar, A.; Laskar, S.G.; Thiagarajan, S. Is Transoral Robotic Surgery (TORS) for oropharyngeal squamous cell carcinoma being done more often than actually indicated? Head Neck 2021, 43, 1376–1377. [Google Scholar] [CrossRef]
- Dahlstrom, K.R.; Bell, D.; Hanby, D.; Li, G.; Wang, L.-E.; Wei, Q.; Williams, M.D.; Sturgis, E.M. Socioeconomic characteristics of patients with oropharyngeal carcinoma according to tumor HPV status, patient smoking status, and sexual behavior. Oral Oncol. 2015, 51, 832–838. [Google Scholar] [CrossRef] [Green Version]
- Milliet, F.; Bozec, A.; Schiappa, R.; Viotti, J.; Modesto, A.; Dassonville, O.; Poissonnet, G.; Guelfucci, B.; Bizeau, A.; Vergez, S.; et al. Metachronous second primary neoplasia in oropharyngeal cancer patients: Impact of tumor HPV status. A GETTEC multicentric study. Oral Oncol. 2021, 122, 105503. [Google Scholar] [CrossRef]
- Milliet, F.; Bozec, A.; Schiappa, R.; Viotti, J.; Modesto, A.; Dassonville, O.; Poissonnet, G.; Guelfucci, B.; Bizeau, A.; Vergez, S.; et al. Synchronous primary neoplasia in patients with oropharyngeal cancer: Impact of tumor HPV status. A GETTEC multicentric study. Oral Oncol. 2020, 112, 105041. [Google Scholar] [CrossRef]
- Martel, M.; Alemany, L.; Taberna, M.; Mena, M.; Tous, S.; Bagué, S.; Castellsagué, X.; Quer, M.; León, X. The role of HPV on the risk of second primary neoplasia in patients with oropharyngeal carcinoma. Oral Oncol. 2016, 64, 37–43. [Google Scholar] [CrossRef] [PubMed]
- Wang, J.; Xi, X.; Shang, W.; Acharya, A.; Li, S.; Savkovic, V.; Li, H.; Haak, R.; Schmidt, J.; Liu, X.; et al. The molecular differences between human papillomavirus-positive and -negative oropharyngeal squamous cell carcinoma: A bioinformatics study. Am. J. Otolaryngol. 2019, 40, 547–554. [Google Scholar] [CrossRef]
- McLaughlin-Drubin, M.E.; Crum, C.P.; Munger, K. Human papillomavirus E7 oncoprotein induces KDM6A and KDM6B histone demethylase expression and causes epigenetic reprogramming. Proc. Natl. Acad. Sci. USA 2011, 108, 2130–2135. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Shinn, J.R.; Davis, S.J.; Lang-Kuhs, K.A.; Rohde, S.; Wang, X.; Liu, P.; Dupont, W.D.; Plummer, D., Jr.; Thorstad, W.L.; Chernock, R.D.; et al. Oropharyngeal Squamous Cell Carcinoma with Discordant p16 and HPV mRNA Results: Incidence and Characterization in a Large, Contemporary United States Cohort. Am. J. Surg. Pathol. 2021, 45, 951–961. [Google Scholar]
- Mirghani, H.; Amen, F.; Moreau, F.; Guigay, J.; Ferchiou, M.; Melkane, A.E.; Hartl, D.M.; Guily, J.L.S. Human papilloma virus testing in oropharyngeal squamous cell carcinoma: What the clinician should know. Oral Oncol. 2014, 50, 1–9. [Google Scholar] [CrossRef]
- Cancer Genome Atlas, N. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 2015, 517, 576–582. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mirghani, H.; Bellera, C.; Delaye, J.; Dolivet, G.; Fakhry, N.; Bozec, A.; Garrel, R.; Malard, O.; Jegoux, F.; Maingon, P.; et al. Prevalence and characteristics of HPV-driven oropharyngeal cancer in France. Cancer Epidemiol. 2019, 61, 89–94. [Google Scholar] [CrossRef]
- Huang, Y.-H.; Yeh, C.-H.; Cheng, N.-M.; Lin, C.-Y.; Wang, H.-M.; Ko, S.-F.; Toh, C.-H.; Yen, T.-C.; Liao, C.-T.; Ng, S.-H. Cystic nodal metastasis in patients with oropharyngeal squamous cell carcinoma receiving chemoradiotherapy: Relationship with human papillomavirus status and failure patterns. PLoS ONE 2017, 12, e0180779. [Google Scholar] [CrossRef] [Green Version]
- Mirghani, H.; Amen, F.; Tao, Y.; Deutsch, E.; Levy, A. Increased radiosensitivity of HPV-positive head and neck cancers: Molecular basis and therapeutic perspectives. Cancer Treat. Rev. 2015, 41, 844–852. [Google Scholar] [CrossRef] [PubMed]
- Liu, C.; Mann, D.; Sinha, U.K.; Kokot, N.C. The molecular mechanisms of increased radiosensitivity of HPV-positive oropharyngeal squamous cell carcinoma (OPSCC): An extensive review. J. Otolaryngol. Head Neck Surg. 2018, 47, 59. [Google Scholar] [CrossRef] [PubMed]
- Culié, D.; Lisan, Q.; Leroy, C.; Modesto, A.; Schiappa, R.; Chamorey, E.; Dassonville, O.; Poissonnet, G.; Guelfucci, B.; Bizeau, A.; et al. Oropharyngeal cancer: First relapse description and prognostic factor of salvage treatment according to p16 status, a GETTEC multicentric study. Eur. J. Cancer 2020, 143, 168–177. [Google Scholar] [CrossRef]
- Wendt, M.; Hammarstedt-Nordenvall, L.; Zupancic, M.; Friesland, S.; Landin, D.; Munck-Wikland, E.; Dalianis, T.; Näsman, A.; Marklund, L. Long-Term Survival and Recurrence in Oropharyngeal Squamous Cell Carcinoma in Relation to Subsites, HPV, and p16-Status. Cancers 2021, 13, 2553. [Google Scholar] [CrossRef]
- Culié, D.; Benezery, K.; Chamorey, E.; Ettaiche, M.; Fernandez, J.; Poissonnet, G.; Riss, J.-C.; Hannoun-Lévi, J.-M.; Chand, M.-E.; Leysalle, A.; et al. Salvage surgery for recurrent oropharyngeal cancer: Post-operative oncologic and functional outcomes. Acta Oto-Laryngol. 2015, 135, 1323–1329. [Google Scholar] [CrossRef] [PubMed]
- Willenbrink, T.J.; Ruiz, E.S.; Cornejo, C.M.; Schmults, C.D.; Arron, S.T.; Jambusaria-Pahlajani, A. Field cancerization: Definition, epidemiology, risk factors, and outcomes. J. Am. Acad. Dermatol. 2020, 83, 709–717. [Google Scholar] [CrossRef] [PubMed]
- Dickey, B.L.; Fan, W.; Bettampadi, D.; Reich, R.R.; Sirak, B.; Abrahamsen, M.; Baggio, M.L.; Galan, L.; Silva, R.C.; Salmerón, J.; et al. Sequential acquisition of human papillomavirus infection between genital and oral anatomic sites in males. Int. J. Cancer 2021, 149, 1483–1494. [Google Scholar] [CrossRef]
- Larish, A.; Yin, L.; Glaser, G.; Moore, E.; Bakkum-Gamez, J.; Routman, D.; Ma, D.; Price, D.; Janus, J.; Price, K.; et al. Human Papillomavirus–Associated Anogenital Pathology in Females with HPV-Positive Oropharyngeal Squamous Cell Carcinoma. Otolaryngol. Neck Surg. 2020, 164, 369–374. [Google Scholar] [CrossRef]
- Nauta, I.; Rietbergen, M.; van Bokhoven, A.; Bloemena, E.; Lissenberg-Witte, B.; Heideman, D.; de Jong, R.B.; Brakenhoff, R.; Leemans, C. Evaluation of the eighth TNM classification on p16-positive oropharyngeal squamous cell carcinomas in the Netherlands and the importance of additional HPV DNA testing. Ann. Oncol. 2018, 29, 1273–1279. [Google Scholar] [CrossRef]
- Rühle, A.; Grosu, A.-L.; Nicolay, N. De-Escalation Strategies of (Chemo)Radiation for Head-and-Neck Squamous Cell Cancers—HPV and Beyond. Cancers 2021, 13, 2204. [Google Scholar] [CrossRef]
- Chen, S.Y.; Last, A.; Ettyreddy, A.; Kallogjeri, D.; Wahle, B.; Chidambaram, S.; Mazul, A.; Thorstad, W.; Jackson, R.S.; Zevallos, J.P.; et al. 20 pack-year smoking history as strongest smoking metric predictive of HPV-positive oropharyngeal cancer outcomes. Am. J. Otolaryngol. 2021, 42, 102915. [Google Scholar] [CrossRef] [PubMed]
- Bouland, C.; Dequanter, D.; Lechien, J.R.; Hanssens, C.; Aubain, N.D.S.; Digonnet, A.; Javadian, R.; Yanni, A.; Rodriguez, A.; Loeb, I.; et al. Prognostic Significance of a Scoring System Combining p16, Smoking, and Drinking Status in a Series of 131 Patients with Oropharyngeal Cancers. Int. J. Otolaryngol. 2021, 2021, 1–6. [Google Scholar] [CrossRef]
- Xiao, R.; Pham, Y.; Ward, M.C.; Houston, N.; Reddy, C.A.; Joshi, N.P.; Greskovich, J.F., Jr.; Woody, N.M.; Chute, D.J.; Lamarre, E.D.; et al. Impact of active smoking on outcomes in HPV+ oropharyngeal cancer. Head Neck 2019, 42, 269–280. [Google Scholar] [CrossRef]
- House, R.; Majumder, M.; Janakiraman, H.; Ogretmen, B.; Kato, M.; Erkul, E.; Hill, E.; Atkinson, C.; Barth, J.; Day, T.A.; et al. Smoking-induced control of miR-133a-3p alters the expression of EGFR and HuR in HPV-infected oropharyngeal cancer. PLoS ONE 2018, 13, e0205077. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mesia, R.; Iglesias, L.; Lambea, J.; Martínez-Trufero, J.; Soria, A.; Taberna, M.; Trigo, J.; Chaves, M.; García-Castaño, A.; Cruz, J. SEOM clinical guidelines for the treatment of head and neck cancer (2020). Clin. Transl. Oncol. 2021, 23, 913–921. [Google Scholar] [CrossRef]
- Colevas, A.D.; Yom, S.; Pfister, D.G.; Spencer, S.; Adelstein, D.; Adkins, D.; Brizel, D.; Burtness, B.; Busse, P.M.; Caudell, J.J.; et al. NCCN Guidelines Insights: Head and Neck Cancers, Version 1.2018. J. Natl. Compr. Cancer Netw. 2018, 16, 479–490. [Google Scholar] [CrossRef] [Green Version]
- Bozec, A.; Poissonnet, G.; Chamorey, E.; Sudaka, A.; Laout, C.; Vallicioni, J.; Demard, F.; Dassonville, O. Transoral and cervical approach without mandibulotomy for oropharynx cancer with fasciocutaneous radial forearm free flap reconstruction. Ann. Otolaryngol. Chir. Cervicofac. 2009, 126, 182–189. [Google Scholar] [CrossRef] [PubMed]
- De Virgilio, A.; Costantino, A.; Mercante, G.; Pellini, R.; Ferreli, F.; Malvezzi, L.; Colombo, G.; Cugini, G.; Petruzzi, G.; Spriano, G. Transoral robotic surgery and intensity-modulated radiotherapy in the treatment of the oropharyngeal carcinoma: A systematic review and meta-analysis. Eur. Arch. Oto-Rhino-Laryngol. 2020, 278, 1321–1335. [Google Scholar] [CrossRef]
- Garrel, R.; Poissonnet, G.; Temam, S.; Dolivet, G.; Fakhry, N.; de Raucourt, D. Review of sentinel node procedure in cN0 head and neck squamous cell carcinomas. Guidelines from the French evaluation cooperative subgroup of GETTEC. Eur. Ann. Otorhinolaryngol. Head Neck Dis. 2017, 134, 89–93. [Google Scholar] [CrossRef] [PubMed]
- Qureshi, H.A.; Abouyared, M.; Barber, B.; Houlton, J.J. Surgical Options for Locally Advanced Oropharyngeal Cancer. Curr. Treat. Options Oncol. 2019, 20, 36. [Google Scholar] [CrossRef]
- Moore, E.J.; Van Abel, K.M.; Price, D.L.; Lohse, C.M.; Olsen, K.D.; Jackson, R.; Martin, E.J. Transoral robotic surgery for oropharyngeal carcinoma: Surgical margins and oncologic outcomes. Head Neck 2018, 40, 747–755. [Google Scholar] [CrossRef] [PubMed]
- Gorphe, P.; Von Tan, J.; El Bedoui, S.; Hartl, D.M.; Auperin, A.; Qassemyar, Q.; Moya-Plana, A.; Janot, F.; Julieron, M.; Temam, S. Early assessment of feasibility and technical specificities of transoral robotic surgery using the da Vinci Xi. J. Robot. Surg. 2017, 11, 455–461. [Google Scholar] [CrossRef]
- López, F.; Fernández-Vañes, L.; García-Cabo, P.; Grilli, G.; Álvarez-Marcos, C.; Llorente, J.L.; Rodrigo, J.P. Selective neck dissection in the treatment of head and neck squamous cell carcinoma patients with a clinically positive neck. Oral Oncol. 2020, 102, 104565. [Google Scholar] [CrossRef]
- Garrel, R.; Poissonnet, G.; Plana, A.M.; Fakhry, N.; Dolivet, G.; Lallemant, B.; Sarini, J.; Vergez, S.; Guelfucci, B.; Choussy, O.; et al. Equivalence Randomized Trial to Compare Treatment on the Basis of Sentinel Node Biopsy Versus Neck Node Dissection in Operable T1-T2N0 Oral and Oropharyngeal Cancer. J. Clin. Oncol. 2020, 38, 4010–4018. [Google Scholar] [CrossRef]
- Gorphe, P.; Temam, S.; Kolb, F.; Qassemyar, Q. Cervical-transoral robotic oropharyngectomy and thin anterolateral thigh free flap. Eur. Ann. Otorhinolaryngol. Head Neck Dis. 2018, 135, 71–74. [Google Scholar] [CrossRef]
- Melan, J.-B.; Philouze, P.; Pradat, P.; Benzerdjeb, N.; Blanc, J.; Ceruse, P.; Fuchsmann, C. Functional outcomes of soft palate free flap reconstruction following oropharyngeal cancer surgery. Eur. J. Surg. Oncol. (EJSO) 2021, 47, 2265–2271. [Google Scholar] [CrossRef]
- Camuzard, O.; Dassonville, O.; Ettaiche, M.; Chamorey, E.; Poissonnet, G.; Berguiga, R.; Leysalle, A.; Benezery, K.; Peyrade, F.; Saada, E.; et al. Primary radical ablative surgery and fibula free-flap reconstruction for T4 oral cavity squamous cell carcinoma with mandibular invasion: Oncologic and functional results and their predictive factors. Eur. Arch. Oto-Rhino-Laryngol. 2016, 274, 441–449. [Google Scholar] [CrossRef] [PubMed]
- Culié, D.; Dassonville, O.; Poissonnet, G.; Riss, J.-C.; Fernandez, J.; Bozec, A. Virtual planning and guided surgery in fibular free-flap mandibular reconstruction: A 29-case series. Eur. Ann. Otorhinolaryngol. Head Neck Dis. 2016, 133, 175–178. [Google Scholar] [CrossRef]
- Bernier, J.; Vermorken, J.B.; Koch, W.M. Adjuvant Therapy in Patients with Resected Poor-Risk Head and Neck Cancer. J. Clin. Oncol. 2006, 24, 2629–2635. [Google Scholar] [CrossRef] [PubMed]
- Boros, A.; Blanchard, P.; Dade, A.; Gorphe, P.; Breuskin, I.; Even, C.; Nguyen, F.; Deutsch, E.; Bidault, F.; Janot, F.; et al. Outcomes in N3 Head and Neck Squamous Cell Carcinoma and Role of Upfront Neck Dissection. Laryngoscope 2020, 131, E846–E850. [Google Scholar] [CrossRef] [PubMed]
- Paximadis, P.A.; Christensen, M.E.; Dyson, G.; Kamdar, D.P.; Sukari, A.; Lin, H.-S.; Yoo, G.H.; Kim, H.E. Up-front neck dissection followed by concurrent chemoradiation in patients with regionally advanced head and neck cancer. Head Neck 2012, 34, 1798–1803. [Google Scholar] [CrossRef] [Green Version]
- Klausner, G.; Troussier, I.; Fabiano, E.; Kreps, S.; Laccourreye, O.; Giraud, P. 881P Impact of neck dissection in N2-3 oropharyngeal squamous-cell carcinomas treated with definitive chemo-radiotherapy: An observational real-life study. Ann. Oncol. 2021, 32, S794–S795. [Google Scholar] [CrossRef]
- Gupta, T.; Sinha, S.; Ghosh-Laskar, S.; Budrukkar, A.; Mummudi, N.; Swain, M.; Phurailatpam, R.; Prabhash, K.; Agarwal, J.P. Intensity-modulated radiation therapy versus three-dimensional conformal radiotherapy in head and neck squamous cell carcinoma: Long-term and mature outcomes of a prospective randomized trial. Radiat. Oncol. 2020, 15, 1–9. [Google Scholar] [CrossRef]
- Tribius, S.; Bergelt, C. Intensity-modulated radiotherapy versus conventional and 3D conformal radiotherapy in patients with head and neck cancer: Is there a worthwhile quality of life gain? Cancer Treat Rev. 2011, 37, 511–519. [Google Scholar] [CrossRef]
- Mazzola, R.; Fiorentino, A.; Ricchetti, F.; Gregucci, F.; Corradini, S.; Alongi, F. An update on radiation therapy in head and neck cancers. Expert Rev. Anticancer. Ther. 2018, 18, 359–364. [Google Scholar] [CrossRef]
- De Felice, F.; Belgioia, L.; Alterio, D.; Bonomo, P.; Maddalo, M.; Paiar, F.; Denaro, N.; Corvò, R.; Merlotti, A.; Bossi, P.; et al. Survival and toxicity of weekly cisplatin chemoradiotherapy versus three-weekly cisplatin chemoradiotherapy for head and neck cancer: A systematic review and meta-analysis endorsed by the Italian Association of Radiotherapy and Clinical Oncology (AIRO). Crit. Rev. Oncol. 2021, 162, 103345. [Google Scholar] [CrossRef]
- Bonner, J.A.; Harari, P.M.; Giralt, J.; Cohen, R.B.; Jones, C.U.; Sur, R.K.; Raben, D.; Baselga, J.; Spencer, S.A.; Zhu, J.; et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2010, 11, 21–28. [Google Scholar] [CrossRef]
- Mehanna, H.; Robinson, M.; Hartley, A.; Kong, A.; Foran, B.; Fulton-Lieuw, T.; Dalby, M.; Mistry, P.; Sen, M.; O’Toole, L.; et al. Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): An open-label randomised controlled phase 3 trial. Lancet 2019, 393, 51–60. [Google Scholar] [CrossRef] [Green Version]
- Haddad, R.; O’Neill, A.; Rabinowits, G.; Tishler, R.; Khuri, F.R.; Adkins, D.; Clark, J.; Sarlis, N.; Lorch, J.; Beitler, J.J.; et al. Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): A randomised phase 3 trial. Lancet Oncol. 2013, 14, 257–264. [Google Scholar] [CrossRef]
- Ang, K.K.; Zhang, Q.; Rosenthal, D.; Nguyen-Tan, P.F.; Sherman, E.J.; Weber, R.S.; Galvin, J.M.; Bonner, J.A.; Harris, J.; El-Naggar, A.K.; et al. Randomized Phase III Trial of Concurrent Accelerated Radiation Plus Cisplatin with or Without Cetuximab for Stage III to IV Head and Neck Carcinoma: RTOG 0522. J. Clin. Oncol. 2014, 32, 2940–2950. [Google Scholar] [CrossRef] [PubMed]
- Hitt, R.; Grau, J.J.; López-Pousa, A.; Berrocal, A.; García-Girón, C.; Irigoyen, A.; Sastre, J.; Martínez-Trufero, J.; Castelo, J.A.B.; Verger, E.; et al. A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer. Ann. Oncol. 2013, 25, 216–225. [Google Scholar] [CrossRef] [PubMed]
- Merlano, M.C.; Denaro, N.; Vecchio, S.; Licitra, L.; Curcio, P.; Benasso, M.; Bagicalupo, A.; Numico, G.; Russi, E.; Corvo’, R.; et al. Phase III Randomized Study of Induction Chemotherapy Followed by Definitive Radiotherapy + Cetuximab Versus Chemoradiotherapy in Squamous Cell Carcinoma of Head and Neck: The INTERCEPTOR-GONO Study (NCT00999700). Oncology 2020, 98, 763–770. [Google Scholar] [CrossRef]
- Yu, Y.; Lee, N.Y. JAVELIN Head and Neck 100: A Phase III trial of avelumab and chemoradiation for locally advanced head and neck cancer. Future Oncol. 2019, 15, 687–694. [Google Scholar] [CrossRef]
- Culié, D.; Schiappa, R.; Modesto, A.; Viotti, J.; Chamorey, E.; Dassonville, O.; Poissonnet, G.; Bizeau, A.; Vergez, S.; Dupret-Bories, A.; et al. Upfront surgery or definitive radiotherapy for p16+ oropharyngeal cancer. A GETTEC multicentric study. Eur. J. Surg. Oncol. (EJSO) 2020, 47, 1389–1397. [Google Scholar] [CrossRef]
- Nichols, A.C.; Theurer, J.; Prisman, E.; Read, N.; Berthelet, E.; Tran, E.; Fung, K.; de Almeida, J.R.; Bayley, A.; Goldstein, D.P.; et al. Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): An open-label, phase 2, randomised trial. Lancet Oncol. 2019, 20, 1349–1359. [Google Scholar] [CrossRef]
- Charters, E.; Wu, R.; Milross, C.; Bogaardt, H.; Freeman-Sanderson, A.; Ballard, K.; Davies, S.; Oates, J.; Clark, J. Swallowing and communication outcomes following primary transoral robotic surgery. Head Neck 2021, 43, 2013–2023. [Google Scholar] [CrossRef]
- Feng, A.L.; Holcomb, A.J.; Abt, N.B.; Mokhtari, T.E.; Suresh, K.; McHugh, C.I.; Parikh, A.S.; Holman, A.; Kammer, R.E.; Goldsmith, T.A.; et al. Feeding Tube Placement Following Transoral Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma. Otolaryngol. Neck Surg. 2021, 01945998211020302. [Google Scholar] [CrossRef]
- Pierre, C.S.; Dassonville, O.; Chamorey, E.; Poissonnet, G.; Ettaiche, M.; Santini, J.; Peyrade, F.; Benezery, K.; Sudaka, A.; Bozec, A. Long-term quality of life and its predictive factors after oncologic surgery and microvascular reconstruction in patients with oral or oropharyngeal cancer. Eur. Arch. Oto-Rhino-Laryngol. 2013, 271, 801–807. [Google Scholar] [CrossRef]
- Rizzo, P.B.; Stellin, M.; Fuson, R.; Marchiori, C.; Gava, A.; Da Mosto, M.C. Long-term quality of life after treatment for locally advanced oropharyngeal carcinoma: Surgery and postoperative radiotherapy versus concurrent chemoradiation. Oral Oncol. 2009, 45, 953–957. [Google Scholar] [CrossRef]
- Kelly, J.R.; Park, H.S.; An, Y.; Yarbrough, W.G.; Contessa, J.N.; Decker, R.; Mehra, S.; Judson, B.L.; Burtness, B.; Husain, Z. Upfront surgery versus definitive chemoradiotherapy in patients with human Papillomavirus-associated oropharyngeal squamous cell cancer. Oral Oncol. 2018, 79, 64–70. [Google Scholar] [CrossRef] [PubMed]
- Kelly, J.; Husain, Z.A.; Burtness, B. Treatment de-intensification strategies for head and neck cancer. Eur. J. Cancer 2016, 68, 125–133. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kamran, S.C.; Qureshi, M.M.; Jalisi, S.; Salama, A.; Grillone, G.; Truong, M.T. Primary surgery versus primary radiation-based treatment for locally advanced oropharyngeal cancer. Laryngoscope 2017, 128, 1353–1364. [Google Scholar] [CrossRef]
- Ranta, P.; Kinnunen, I.; Jouhi, L.; Vahlberg, T.; Back, L.J.J.; Halme, E.; Koivunen, P.; Autio, T.; Pukkila, M.; Irjala, H. Long-term Quality of Life After Treatment of Oropharyngeal Squamous Cell Carcinoma. Laryngoscope 2020, 131. [Google Scholar] [CrossRef] [PubMed]
- Jacobs, D.; Torabi, S.J.; Park, H.S.; Rahmati, R.; Young, M.R.; Mehra, S.; Judson, B.L. Revisiting the Radiation Therapy Oncology Group 1221 Hypothesis: Treatment for Stage III/IV HPV-Negative Oropharyngeal Cancer. Otolaryngol. Neck Surg. 2020, 164, 1240–1248. [Google Scholar] [CrossRef] [PubMed]
- Trinh, J.-M.; Thomas, J.; Salleron, J.; Henrot, P. Differences in clinical and imaging characteristics between p16-positive non-smokers and p16-positive smokers or p16-negative patients in oropharyngeal carcinoma. Sci. Rep. 2021, 11, 1–11. [Google Scholar] [CrossRef]
- Seikaly, H.; Biron, V.L.; Zhang, H.; O’Connell, D.A.; Côté, D.W.J.; Ansari, K.; Williams, D.C.; Puttagunta, L.; Harris, J.R. Role of primary surgery in the treatment of advanced oropharyngeal cancer. Head Neck 2015, 38, E571–E579. [Google Scholar] [CrossRef]
- Mazarro, A.; de Pablo, A.; Puiggròs, C.; Velasco, M.M.; Saez, M.; Pamias, J.; Bescós, C. Indications, reconstructive techniques, and results for total glossectomy. Head Neck 2016, 38, E2004–E2010. [Google Scholar] [CrossRef]
- Fulcher, C.D.; Haigentz, M.; Ow, T.J. The Education Committee of the American Head and Neck Society (AHNS) AHNS Series: Do you know your guidelines? Principles of treatment for locally advanced or unresectable head and neck squamous cell carcinoma. Head Neck 2017, 40, 676–686. [Google Scholar] [CrossRef]
- Soba, E.; Budihna, M.; Smid, L.; Gale, N.; Lesnicar, H.; Zakotnik, B.; Strojan, P. Prognostic value of some tumor markers in unresectable stage IV oropharyngeal carcinoma patients treated with concomitant radiochemotherapy. Radiol. Oncol. 2015, 49, 365–370. [Google Scholar] [CrossRef] [Green Version]
- Bhattasali, O.; Ryoo, J.J.; Thompson, L.; Abdalla, I.A.; Chen, J.; Iganej, S. Impact of chemotherapy regimen on treatment outcomes in patients with HPV-associated oropharyngeal cancer with T4 disease treated with definitive concurrent chemoradiation. Oral Oncol. 2019, 95, 74–78. [Google Scholar] [CrossRef]
- Gillison, M.L.; Trotti, A.M.; Harris, J.; Eisbruch, A.; Harari, P.M.; Adelstein, D.J.; Jordan, R.C.K.; Zhao, W.; Sturgis, E.M.; Burtness, B.; et al. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): A randomised, multicentre, non-inferiority trial. Lancet 2018, 393, 40–50. [Google Scholar] [CrossRef]
- Wang, H.; Zhao, Q.; Zhang, Y.; Zhang, Q.; Zheng, Z.; Liu, S.; Liu, Z.; Meng, L.; Xin, Y.; Jiang, X. Immunotherapy Advances in Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Its Relationship with Human Papillomavirus. Front. Immunol. 2021, 12, 2333. [Google Scholar] [CrossRef]
- Guigay, J.; Aupérin, A.; Fayette, J.; Saada-Bouzid, E.; Lafond, C.; Taberna, M.; Geoffrois, L.; Martin, L.; Capitain, O.; Cupissol, D.; et al. Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): A multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2021, 22, 463–475. [Google Scholar] [CrossRef] [PubMed]
- Zafereo, M. Surgical Salvage of Recurrent Cancer of the Head and Neck. Curr. Oncol. Rep. 2014, 16, 1–6. [Google Scholar] [CrossRef] [PubMed]
- Bagley, A.F.; Garden, A.S.; Reddy, J.P.; Moreno, A.C.; Frank, S.J.; Rosenthal, D.I.; Morrison, W.H.; Gunn, G.B.; Fuller, C.D.; Shah, S.J.; et al. Highly conformal reirradiation in patients with prior oropharyngeal radiation: Clinical efficacy and toxicity outcomes. Head Neck 2020, 42, 3326–3335. [Google Scholar] [CrossRef] [PubMed]
- Szturz, P.; Nevens, D.; Vermorken, J.B. Oligometastatic Disease Management: Finding the Sweet Spot. Front. Oncol. 2020, 10, 617793. [Google Scholar] [CrossRef]
- Burtness, B.; Harrington, K.; Greil, R.; Soulières, D.; Tahara, M.; de Castro, G.; Psyrri, A.; Basté, N.; Neupane, P.; Bratland, Å.; et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): A randomised, open-label, phase 3 study. Lancet 2019, 394, 1915–1928. [Google Scholar] [CrossRef]
- Nichols, A.C.; Lang, P.; Prisman, E.; Berthelet, E.; Tran, E.; Hamilton, S.; Wu, J.; Fung, K.; De Almeida, J.R.; Bayley, A.; et al. Treatment de-escalation for HPV-associated oropharyngeal squamous cell carcinoma with radiotherapy vs. trans-oral surgery (ORATOR2): Study protocol for a randomized phase II trial. BMC Cancer 2020, 20, 1–13. [Google Scholar] [CrossRef] [Green Version]
- Sun, X.-S.; Tao, Y.; Le Tourneau, C.; Pointreau, Y.; Sire, C.; Kaminsky, M.-C.; Coutte, A.; Alfonsi, M.; Boisselier, P.; Martin, L.; et al. Debio 1143 and high-dose cisplatin chemoradiotherapy in high-risk locoregionally advanced squamous cell carcinoma of the head and neck: A double-blind, multicentre, randomised, phase 2 study. Lancet Oncol. 2020, 21, 1173–1187. [Google Scholar] [CrossRef]
- Tao, Y.; Aupérin, A.; Sun, X.; Sire, C.; Martin, L.; Coutte, A.; Lafond, C.; Miroir, J.; Liem, X.; Rolland, F.; et al. Avelumab–cetuximab–radiotherapy versus standards of care in locally advanced squamous-cell carcinoma of the head and neck: The safety phase of a randomised phase III trial GORTEC 2017-01 (REACH). Eur. J. Cancer 2020, 141, 21–29. [Google Scholar] [CrossRef]
- Mirghani, H.; Amen, F.; Blanchard, P.; Moreau, F.; Guigay, J.; Hartl, D.; Guily, J.L.S. Treatment de-escalation in HPV-positive oropharyngeal carcinoma: Ongoing trials, critical issues and perspectives. Int. J. Cancer 2014, 136, 1494–1503. [Google Scholar] [CrossRef]
- Wotman, M.T.; Miles, B.A.; Bakst, R.L.; Posner, M.R. A proposal for risk-based and strategy-adapted de-escalation in human papillomavirus-positive oropharyngeal squamous cell carcinoma. Cancer 2021, in press. [Google Scholar] [CrossRef]
- Gabani, P.; Lin, A.J.; Barnes, J.; Oppelt, P.; Adkins, D.R.; Rich, J.T.; Zevallos, J.P.; Daly, M.D.; Gay, H.A.; Thorstad, W.L. Radiation therapy dose de-escalation compared to standard dose radiation therapy in definitive treatment of HPV-positive oropharyngeal squamous cell carcinoma. Radiother. Oncol. 2019, 134, 81–88. [Google Scholar] [CrossRef] [PubMed]
Main Characteristics | HPV-Positive OPSCC | HPV-Negative OPSCC |
---|---|---|
Gender | Male >> female | Male >> female |
Alcohol/tobacco | Low consumption | High consumption |
General health status | Good | Poor, high comorbidity level |
Educ./economic level | High | Low |
Tumor location | Tongue base and tonsils | All parts of the oropharynx |
Primary tumor | T1/T2, superficial/exophytic tumor | T3/T4, ulcerative and infiltrative tumor |
Lymph-node involvement | Extremely frequent, multiple, cystic neck mass(es) | Moderately frequent, limited number of metastases |
Second primary cancer | Very low risk | 10 to 15% (head and neck, lung, esophagus +++) |
Sensitivity to RT/CT | High | Variable, low to moderate |
Prognosis | Good | Poor to intermediate |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Bozec, A.; Culié, D.; Poissonnet, G.; Demard, F.; Dassonville, O. Current Therapeutic Strategies in Patients with Oropharyngeal Squamous Cell Carcinoma: Impact of the Tumor HPV Status. Cancers 2021, 13, 5456. https://doi.org/10.3390/cancers13215456
Bozec A, Culié D, Poissonnet G, Demard F, Dassonville O. Current Therapeutic Strategies in Patients with Oropharyngeal Squamous Cell Carcinoma: Impact of the Tumor HPV Status. Cancers. 2021; 13(21):5456. https://doi.org/10.3390/cancers13215456
Chicago/Turabian StyleBozec, Alexandre, Dorian Culié, Gilles Poissonnet, François Demard, and Olivier Dassonville. 2021. "Current Therapeutic Strategies in Patients with Oropharyngeal Squamous Cell Carcinoma: Impact of the Tumor HPV Status" Cancers 13, no. 21: 5456. https://doi.org/10.3390/cancers13215456